IP Library Granted Patent US 11,524,945
Granted Patent B2
US 11,524,945 · App. 16/963,968 · Granted Dec 13, 2022

Compounds for treating ILK-mediated diseases

Inventors: Jun Qin (Solon, OH); Koichi Fukuda (Cleveland Heights, OH); Julia Vaynberg (Rocky River, OH); Suguna Rachakonda (Copley, OH)
Assignee: The Cleveland Clinic Foundation
C07D239/94A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,524,945
App. No.
16/963,968
Granted
Dec 13, 2022
Kind
B2
Abstract

The present invention relates to compounds that are modulators of Integrin Linked Kinase (ILK), and methods of treating diseases with such compounds. In certain embodiments, the compounds are within Formulas I-VII (e.g., Csbl-1). In some embodiments, the compounds are used to treat an ILK-mediated disease, such as cancer (e.g., triple negative breast cancer) or an inflammatory disease.

Claims (44)

1. A compound having a structure of Formula I, or a pharmaceutically acceptable salt thereof, wherein Formula I is:

wherein R1-R7, R13-R16 and X1 are each an atom or group independently selected from: hydrogen, deuterium, trifluoromethyl, lower alkyl, lower alkoxy, aryloxy, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, formyl, lower alkylcarbonyl, arylcarbonyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, and aryl;

wherein at least one of R1-R7, R14-R19 and X1 is not hydrogen;

wherein R17-R19 are each independently selected from: hydrogen, deuterium, trifluoromethyl, lower alkyl, lower alkoxy, aryloxy, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, lower alkylcarbonyl, arylcarbonyl, formyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, formamido, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, aryl, —OH, —CH 2 —OH, —CH 2 —NH 2 , —CH 2 —NO 2 , —CH 2 —COOH, —CH 2 —CN, and —CH 2 —CONH 2 ;

wherein R8-R12 are each independently selected from: hydrogen, deuterium, fluorine, chlorine, bromine, and iodine;

wherein X2 is N or CH;

wherein X3 is NH, O, S, or CH 2 ; and

wherein X4 is selected from: fluorine, chlorine, bromine, iodine, —CN, and —C≡CY where Y is hydrogen or deuterium.

2. A compound having a structure of Formula II, or a pharmaceutically acceptable salt thereof, wherein Formula II is:

wherein R1-R14, and R20-R23 are each an atom or group independently selected from: hydrogen, deuterium, lower alkyl, lower alkoxy, aryloxy, trifluoromethyl, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, formyl, lower alkylcarbonyl, arylcarbonyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, formamido, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, and aryl, and

wherein at least one among R1-R14, R21-R2 is not hydrogen;

wherein R24-R26 are each independently selected from: hydrogen, deuterium, lower alkyl, lower alkoxy, aryloxy, trifluoromethyl, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, lower alkylcarbonyl, arylcarbonyl, formyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, formamido, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, aryl, —OH, —CH 2 —OH, —CH 2 —NH 2 , —CH 2 —NO 2 , —CH 2 —COOH, —CH 2 —CN, and —CH 2 —CONH 2 ;

wherein R15-R19 are each independently selected from: hydrogen, deuterium, fluorine, chlorine, bromine, and iodine;

wherein X1 is nitrogen or CH;

wherein X2 is selected from: NH, O, S, and CH 2 ; and

wherein X3 is selected from: fluorine, chlorine, bromine, iodine, —CN, and —C≡CY where Y is hydrogen or deuterium.

3. A compound having a structure of Formula III, or a pharmaceutically acceptable salt thereof, wherein Formula III is:

wherein X1 is n-propylene, and wherein 1 to 6 hydrogen atoms are optionally replaced in said n-propylene with deuterium atoms;

wherein X2 is selected from: —OH, —OD, —OCH 3 , —OCH 2 D, —OCHD 2 , and —OCD 3 , wherein D is deuterium;

wherein X3 is N or CH;

wherein X4 is selected from: NH, O, S, and CH 2 ;

X5 is selected from: fluorine, chlorine, bromine, iodine, —CN, and —C≡CY where Y is hydrogen or deuterium:

wherein R1-R8 are each independently selected from: hydrogen and deuterium;

wherein R9-R13 are each independently selected from: hydrogen, deuterium, fluorine, chlorine, bromine, and iodine;

wherein R14-R17 are each an atom or group independently selected from: hydrogen, deuterium, lower alkyl, lower alkoxy, aryloxy, trifluoromethyl, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, formyl, lower alkylcarbonyl, arylcarbonyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, formamido, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, and aryl,

wherein at least one among R14-R20 is not hydrogen; and

wherein R18-R20 are each independently selected from: hydrogen, deuterium, lower alkyl, lower alkoxy, aryloxy, trifluoromethyl, trifluoromethoxy, —SCF 3 , cyano, nitro, amino, lower alkylamino, lower dialkylamino, mercapto, lower alkylthio, arylthio, formyl, lower alkylcarbonyl, arylcarbonyl, lower alkylcarboxy, arylcarboxy, lower alkoxylcarboxy, aryloxylcarboxy, formamido, lower alkanoylamino, arylcarbonylamino, carbamido, lower alkylcarbamido, arylcarbamido, aminocarboxy, lower alkylaminocarboxy, arylaminocarboxy, trifluoroacetyl, halogen, hydroxylcarbonyl, lower alkoxylcarbonyl, aryloxycarbonyl, sulfinyl, lower alkylsulfinyl, arylsulfinyl, sulfonyl, lower alkylsulfonyl, arylsulfonyl, sulfonamido, lower alkylsulfonamido, arylsulfonamido, aryl, —OH, —CH 2 —OH, —CH 2 —NH 2 , —CH 2 —NO 2 , —CH 2 —COOH, —CH 2 —CN, and —CH 2 —CONH 2 .

4. A compound selected from the group consisting of:

5. A method of treating triple-negative breast cancer in a subject in need thereof, comprising: administering a compound of claim 1 to the subject.

6. The method of claim 1 , wherein said subject is a human.

7. The method of claim 5 , wherein said compound is co-administered with an anti-cancer agent and/or an anti-inflammatory agent.

8. The method of claim 5 , wherein said treating comprises administering between 0.05-3000 mg of said compound to said subject.

9. The method of claim 5 , wherein said treating comprises administering between 25-600 mg of said compound to said subject.

10. The method of claim 5 , wherein said treating comprises administering 25-600 mg to said subject per day for at least two days.

11. A method of treating triple-negative breast cancer in a subject in need thereof, comprising: administering a compound of claim 2 to the subject.

12. The method of claim 11 , wherein said subject is a human.

13. A method of treating triple-negative breast cancer in a subject in need thereof, comprising: administering a compound of claim 3 to the subject.

14. The method of claim 13 , wherein said subject is a human.

15. A method of treating triple-negative breast cancer in a subject in need thereof, comprising: administering a compound of claim 4 to the subject.

16. The method of claim 15 , wherein said subject is a human.

17. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a compound of claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: QIN, JUN; VAYNBERG, JULIA; FUKUDA, KOICHI; RACHAKONDA, SUGUNA
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 054916/0408 →
CONFIRMATORY LICENSE Recorded Aug 3, 2020
From: CLEVELAND CLINIC FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053379/0045 →
Continuity (2)
Provisional Application 62621941 · Jan 25, 2018
Related Publication 20210114993A1 · Apr 22, 2021